China Opposes Proposed US Investment Restrictions Targeting Biotech Sector and National Security
The Chinese government on Saturday voiced its stern opposition to a new proposal from the U.S. Treasury Department that seeks to broaden and intensify restrictions on American investment in China. The Ministry of Commerce in Beijing characterized the move as discriminatory and a misuse of national security arguments to interfere with global market dynamics.
The official statement from Beijing labeled the proposed restrictions “a typical example of an overly broad application of national security concerns.” This response follows a recent initiative by the Trump administration to include biotechnology in a list of sensitive sectors subject to investment limits. The U.S. has increasingly targeted high-tech industries in its “foreign adversary” framework, citing concerns that American capital and expertise could bolster the strategic capabilities of rival nations.
Chinese officials argued that these new barriers directly contradict the “important consensus” reached during previous meetings between the presidents of the United States and China. The Ministry of Commerce warned that such policies would not only damage bilateral economic and trade cooperation but would also ultimately harm the interests of U.S. companies that currently operate in or partner with the Chinese market.
“China urges the U.S. to respect the laws of the market economy, cease the overbroad application of the concept of national security, stop politicizing and weaponizing economic and trade issues, and create a favorable environment for China-U.S. economic and trade cooperation,” the ministry’s statement read.
The escalation comes as the biotechnology sector becomes a central focus of trans-Pacific trade tensions. While Washington seeks to curb China’s advances in the field—represented by state-of-the-art facilities like the Synthetic Biology Infrastructure hub in Shenzhen—many American drugmakers have grown increasingly dependent on Chinese firms for the development and supply of new medicines. New restrictions could disrupt these established financial and scientific ties, potentially slowing the progress of pharmaceutical innovation and increasing costs for U.S. firms.
Beijing has signaled that it will not remain passive as the situation develops. The Ministry of Commerce stated it would “closely monitor developments” as the proposal moves through the U.S. regulatory process and emphasized that China “reserves the right to take corresponding measures” should the restrictions be finalized. This warning suggests that American firms could face retaliatory barriers or regulatory hurdles within the Chinese market, further complicating the economic relationship between the world’s two largest economies.
